Chiasma (Israel), LTD Company Profile

05:33 EDT 22nd September 2018 | BioPortfolio

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the GI wall, portal system and then to the systemic circulation. Chiasma creates its internal pipeline by selecting approved macromolecules that are currently available in injectable form, changing the route of administration to oral and evaluating them for new indications, thereby creating new drugs that will take advantage of the 505(b)(2) regulatory route in the US and similar regulations in other countries.

Chiasma’s lead candidate, Octreolin™, is a product in capsule form (administered orally) that contains octreotide acetate, a 1.0 kDa peptide in the TPE formulation. Octreolin has successfully completed a Phase I clinical study evaluating its safety and pharmacokinetics (PK). Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate. In addition, no serious adverse safety events were reported. Chiasma intends to begin a pivotal trial by the end of 2010 for acromegaly, a hormonal disorder that results from an excess of growth hormone (GH). The pool of patients eligible for Octreolin treatment is estimated to be between 10,000 and 15,000 in the US and an equal number in Europe.

Octreolin is also being developed as an oral treatment for patients with Portal Hypertension (PHT); no drugs are approved for PHT in the US. A Phase 2 trial for this new indication is expected to start in December of 2010.

The Company is also developing: (1) An oral peptide (switch from injectable) for a new CNS indication; and (2) An oral protein (switch from injectable) for a viral disease that may also result in improvements to the label.


POB 45182
10 Hartom Street


Phone: 972-2-571-5885
Fax: 972-2-571-5886

News Articles [297 Associated News Articles listed on BioPortfolio]

GapSummit: Lessons for young scientists and innovators

Chiasma is one of our sister organisations; it operates across New Zealand, connecting young scientists with industry, and providing them with professional development. Jessica Chiang, one of our GapS...

Chiasma ends enrolment in MPOWERED trial for acromegaly

Chiasma has completed patient enrolment in the MPOWERED trial, a Phase lll clinical study of octreotide capsules to treat patients...Read More... The post Chiasma ends enrolment in MPOWERED trial for ...

Chiasma (CHMA) Announced Two Clinical / Regulatory Achievements - Slideshow

Takeda Israel Awarded the Best Place to Work in Israel for 2018

TEL AVIV, Israel–(BUSINESS WIRE)–Takeda Israel was recognized as a best place to work in Israel for 2018, according to the annual Workplace program driven by the global research firm BPTW ...

Chiasma shares surge after FDA agrees to redefine late-stage study endpoints

The biopharma is developing a drug to treat acromegaly, a pituitary gland disorder

Spotlight On Israel: Accessing Private Cash For Novel Technologies

Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only...   

Saudi prince says Israel has 'right' to its land

The crown prince and de facto leader of Saudi Arabia said Israel has a "right" to a homeland, a notable shift in the kingdom's position published Monday. Saudi Arabia and Israel still have no formal ...

Cellcom Israel Announces Appointment of Director

NETANYA, Israel, March 25, 2018/PRNewswire/ -- Cellcom Israel Ltd. (NYSE: CEL) (TASE: CEL) (hereinafter: the "Company") announced today that the Company's Board of Read more...

PubMed Articles [116 Associated PubMed Articles listed on BioPortfolio]

High Endemicity and Distinct Phylogenetic Characteristics of Sindbis Virus in Israel.

Sindbis virus (SINV) is a mosquito-borne Alphavirus responsible for outbreaks of SINV disease, mainly in north Europe. SINV has been isolated from mosquitoes in Israel since the 1980s but SINV disease...

Spread of Carbapenem and Colistin-Resistant Klebsiella pneumoniae ST512 Clinical Isolates in Israel: A Cause for Vigilance.

Genomic and phenotypic characterization of resistance mechanisms to carbapenems and colistin in Klebsiella pneumoniae strains isolated from the Shaare Zedek Medical Center (Jerusalem, Israel).

Frailty measurement and its contribution to clinical care and health services: a commentary.

Frailty is associated with poorer quality of life and higher healthcare utilization and spending. Despite its importance, no clear consensus exists on the definition of frailty. The recent IJHPR artic...

Ethnicity-related trends in gynecologic malignancies in Israel, 1993-2013.

To describe trends and ethnic differences in incidence of gynecologic cancer in Israel.

Elevated cancer risk in Holocaust survivors residing in Israel: A retrospective cohort study.

The purpose of this study was to examine the incidence of malignant diseases among Holocaust survivors in Israel compared with European and American immigrants who did not experience the Holocaust.

Clinical Trials [147 Associated Clinical Trials listed on BioPortfolio]

Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups. Also the...

Israeli Multi Ethnic Centenarian Project

This study will systematically assess epigenome methylation changes in participants of the Israel multi-ethnic centenarian study cohort, which includes citizens of Israel aged 95 years and...

Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population

The aim of the present study was to describe the incidence and prevalence of IBD in non Jewish Israel population

Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel

Sickle cell anemia and sickle cell thalassemia are frequent diseases among the israeli arab population. The purpose of this study is to assess the clinical characteristics of the patients ...

Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District

The incidence of early neonatal GBS (group B Streptococcus) infection in the Nazareth Hospital through the years 2006-2013 has been higher compared to the national average. On reviewing al...

Companies [241 Associated Companies listed on BioPortfolio]

Chiasma (Israel), LTD

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small mol...

Chiasma, Inc.

ILSI Biomed Israel 2011

The ILSI Biomed Israel 2011 is the central annual event of Israel's life science industry. It consists of an international professional conference, targeted at the best experts an...

EpiSafe Medical Devices Ltd

EpiSafe is a privately held medical device company dedicated to the development and manufacture of medical devices for the oral cavity. It was founded in 2002 by Eran Lavi, who serves as CEO of the co...

IATI-BioMed Conference

IATI, run by CEO Karin Mayer Rubinstein is the largest umbrella organization representing the hi-tech and life sciences industries. With over 450 members, its mission is to streng...

More Information about "Chiasma (Israel), LTD" on BioPortfolio

We have published hundreds of Chiasma (Israel), LTD news stories on BioPortfolio along with dozens of Chiasma (Israel), LTD Clinical Trials and PubMed Articles about Chiasma (Israel), LTD for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiasma (Israel), LTD Companies in our database. You can also find out about relevant Chiasma (Israel), LTD Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...

Corporate Database Quicklinks

Searches Linking to this Company Record